clinicaladvisor.com1d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Nasdaq14d
Vertex announces FDA exands approval for Trikafta
Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis ages 2 and older who have ...
Morningstar14d
Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
The medicine, called trikafta, can treat cystic fibrosis patients who have at least one F508del mutation in the transmembrane conductance regulator gene or a mutation that is responsive to ...
Yahoo Finance11d
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
The drug is also eligible for use in CF patients who have discontinued Trikafta or Vertex’s other CF medicines. Similar regulatory filings are also under review in Europe. However, the drug’s ...
Monthly Prescribing Reference8d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
Trikafta is supplied in the following dosage strengths and formulations: Elexacaftor 50mg, tezacaftor 25mg, and ivacaftor 37.5mg with ivacaftor 75mg (tablet); Elexacaftor 100mg, tezacaftor 50mg ...
Business Insider14d
Vertex' Trikafta Gets Expanded FDA Approval For Cystic Fibrosis Treatment
FDA has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane ...